Obsidian Therapeutics director reports option holdings

Obsidian Therapeutics, Inc. director Maria Fardis reported her initial holdings of stock options.

Rhea-AI Filing Summary

Obsidian Therapeutics, Inc. director Maria Fardis reported her initial holdings of stock options. She holds four direct option positions, each with an exercise price of $0.78 per share and expirations in 2031, 2032, 2033 and 2034, covering underlying common stock. Options expiring in 2031, 2032 and 2033 cover 355,000, 290,000 and 80,000 shares and are fully vested and exercisable. The option expiring in 2034 covers 497,500 shares that vest in sixteen equal quarterly installments following June 25, 2024, conditioned on her continued service.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Fardis Maria

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F2	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 1,222,500 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying this option are fully vested and exercisable.
2. F2. The shares underlying this option vest in sixteen (16) equal quarterly installments following June 25, 2024, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Exercise price: $0.78 per share Underlying shares option 1: 355,000 shares Underlying shares option 2: 290,000 shares +3 more

6 metrics

Exercise price $0.78 per share Exercise price for all reported stock options held by Maria Fardis

Underlying shares option 1 355,000 shares Fully vested option expiring September 20, 2031

Underlying shares option 2 290,000 shares Fully vested option expiring January 26, 2032

Underlying shares option 3 80,000 shares Fully vested option expiring January 3, 2033

Underlying shares option 4 497,500 shares Option expiring June 24, 2034, vesting in sixteen equal quarterly installments

Vesting schedule installments 16 quarterly installments Vesting schedule for 497,500-share option after June 25, 2024

Key Terms

Stock Option (Right to Buy), fully vested and exercisable, vest in sixteen (16) equal quarterly installments

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

fully vested and exercisable financial

"The shares underlying this option are fully vested and exercisable."

vest in sixteen (16) equal quarterly installments financial

"The shares underlying this option vest in sixteen (16) equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Obsidian Therapeutics (OBX) disclose about Maria Fardis in this Form 3?

The filing shows Maria Fardis is a director of Obsidian Therapeutics and reports her initial stock option holdings, including fully vested options and options that vest quarterly, all with a $0.78 exercise price.

How many Obsidian Therapeutics (OBX) shares are covered by Maria Fardis’s fully vested options?

Three option grants held by Maria Fardis are fully vested and exercisable, covering 355,000, 290,000, and 80,000 shares of Obsidian Therapeutics common stock, all at an exercise price of $0.78 per share.

What is the vesting schedule for Maria Fardis’s 2034 stock option at Obsidian Therapeutics (OBX)?

The 2034-expiring option for 497,500 underlying shares vests in sixteen equal quarterly installments after June 25, 2024, subject to Maria Fardis’s continued service on each vesting date.

What are the expiration dates of Maria Fardis’s stock options reported for Obsidian Therapeutics (OBX)?

Maria Fardis’s reported stock options expire on September 20, 2031, January 26, 2032, January 3, 2033, and June 24, 2034, each relating to common stock with a $0.78 exercise price.

Were any Obsidian Therapeutics (OBX) shares bought or sold in this Maria Fardis Form 3?

No buy or sell transactions are reported. The Form 3 only lists existing stock option holdings for Maria Fardis, without any exercise, purchase, or sale of Obsidian Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 07:10 PM Accepted by SEC EDGAR 08/03/2026 - 06:41 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fardis Maria

(Last) (First) (Middle)

OBSIDIAN THERAPEUTICS, INC.

1030 MASSACHUSETTS AVE

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026

3. Issuer Name and Ticker or Trading Symbol
Obsidian Therapeutics, Inc. [ OBX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	09/20/2031	Common Stock	355,000	$0.78	D
Stock Option (Right to Buy)	(1)	01/26/2032	Common Stock	290,000	$0.78	D
Stock Option (Right to Buy)	(1)	01/03/2033	Common Stock	80,000	$0.78	D
Stock Option (Right to Buy)	(2)	06/24/2034	Common Stock	497,500	$0.78	D

Explanation of Responses:

1. The shares underlying this option are fully vested and exercisable.

2. The shares underlying this option vest in sixteen (16) equal quarterly installments following June 25, 2024, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Gabriela Morales-Rivera, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)